CYCC (CYCLACEL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYCC (CYCLACEL)

CYCC 1.435

-1.7%

Dec 24 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	2/17/2010 8:41:59 AM
	of 6

This may be the same news as last week? 7:03AM Cyclacel Pharma reports new study in clinical cancer research demonstrates potential for Cyclacel's seliciclib in treating breast cancer resistant to hormone therapy. (CYCC) 2.40 : Co announced that a newly published study demonstrates that the company's seliciclib (CYC202 or R-roscovitine), an orally available inhibitor of multiple cyclin-dependent kinases (CDKs), reversed resistance to the aromatase inhibitor letrozole (Femara) and killed hormone receptor positive breast cancer cells that had become insensitive to the effects of letrozole. The new study was published in the current edition of Clinical Cancer Research.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next